PNC-27
p53(12-26)-MRP chimeric peptide, p53-penetratin chimeric peptide, PNC-27 anticancer peptide
PNC-27 is a 32-residue laboratory construct: residues 12 to 26 of the p53 tumour suppressor, which form its HDM-2 binding domain, fused to a membrane-penetrating leader sequence. In cell culture it kills cancer cells and spares normal ones by forming pores in the membrane. It has never been tested in a human clinical trial, it is not a cosmetic or dermatological compound, and the FDA has warned consumers against products sold online as PNC-27 for cancer treatment.
Mechanism
The p53 tumour suppressor is normally held in check by HDM-2 (the human homologue of MDM2), which binds p53's N-terminal transactivation domain and targets it for degradation. Residues 12 to 26 of p53 constitute that binding interface. PNC-27 reproduces this fifteen-residue stretch and appends a seventeen-residue cationic, tryptophan-rich membrane residency peptide (MRP) leader, referred to in this literature as a penetratin sequence, to give a 32-mer.
The proposed mechanism is deliberately not the obvious one. PNC-27 is not thought to work by freeing intracellular p53 from HDM-2. Instead, the observation driving the field is that many transformed cells display HDM-2 in the plasma membrane, which several untransformed cell lines do not. PNC-27 is reported to bind this membrane-resident HDM-2 in a p53-peptide-like conformation, and the peptide-protein assemblies then form ring-shaped transmembrane pore structures, visualised by immuno-scanning electron microscopy as differently sized gold-labelled particles in roughly 1:1 ratios arranged in layered rings near the cell surface. These pores collapse membrane integrity and the cell dies by necrosis rather than apoptosis, independently of p53 status. Later work adds a second target: interaction with mitochondrial membranes causing mitochondrial disruption.
Selectivity, in this model, comes from the differential membrane display of HDM-2 between transformed and normal cells. Two control experiments carry most of the weight. First, transfecting a plasmid expressing full-length HDM-2 with a membrane-localisation signal into untransformed MCF-10-2A cells, which are not normally susceptible, rendered them susceptible to PNC-27. Second, the control peptide PNC-29, which carries the same membrane leader attached to a different cargo sequence, is not cytotoxic to cancer cells. Together these are well-designed controls and the strongest evidence for the mechanism.
What the research shows
The preclinical literature spans roughly two decades and is largely produced by a single collaborating group centred on Matthew Pincus and Josef Michl, with authors also affiliated to NomoCan Pharmaceuticals and named as inventors on patents covering PNC-27 and PNC-28. Sarafraz-Yazdi and colleagues (2010) showed that the three-dimensional structure of the p53 residues in PNC-27 is superimposable on the same residues bound to HDM-2, found significant HDM-2 in the membranes of a range of cancer cell lines but not several untransformed lines, demonstrated colocalisation of PNC-27 with membrane-bound HDM-2, and (the key experiment) made resistant untransformed MCF-10-2A cells susceptible by transfecting membrane-targeted HDM-2 into them. Work on the related shorter analogue PNC-28 (Michl and colleagues, 2006) demonstrated cytotoxicity to cancer cells and inhibition of pancreatic cancer growth in xenograft models, and Bowne and colleagues (2008) established that the mode of death is necrosis rather than apoptosis. Davitt and colleagues (2014) extended the finding to K562 leukaemia cells (a p53-null, poorly differentiated non-solid tumour line) with near-complete killing, no effect on murine leukocyte controls, and no effect from the PNC-29 control peptide. The 2022 Biomedicines paper provided conformational-energy and immuno-electron-microscopy evidence for the pore structure, and a 2024 paper added mitochondrial membrane disruption and showed that a monoclonal antibody against the p53 binding site of HDM-2 blocks PNC-27-induced necrosis.
That is a coherent and internally consistent body of work. It is also, without exception, preclinical. There is no registered clinical trial on ClinicalTrials.gov, no phase 1 safety and dose-finding study, no human pharmacokinetics, and no published human outcome data of any kind. The gap between 'kills cancer cells in a dish and shrinks xenografts in a mouse' and 'treats cancer in a person' is where the overwhelming majority of oncology candidates fail, and PNC-27 has not attempted the crossing.
Meanwhile the compound is sold directly to cancer patients online, including as an inhalation solution, with claims that it treats or cures cancer. The FDA has warned consumers not to purchase or use PNC-27 products marketed as a cancer treatment, and reported finding the bacterium Variovorax paradoxus in a PNC-27 inhalation solution sample. Variovorax paradoxus is an environmental organism capable of causing serious infection in immunocompromised people, which describes much of the intended market. This is arguably the most consequential fact about PNC-27 as it currently exists in the world, and it is not a scientific finding about the peptide at all.
Evidence assessment
Preclinical only
All published work is in vitro or in animal xenograft models; no human clinical trial of PNC-27 has ever been registered or conducted, and the FDA has warned the public against products sold as PNC-27.
Tiers are applied consistently across the library and re-checked when new trials read out. Read the grading method.
Key studies
Anticancer peptide PNC-27 adopts an HDM-2-binding conformation and kills cancer cells by binding to HDM-2 in their membranes Preclinical only
The p53 residues of PNC-27 are structurally superimposable on the same residues bound to HDM-2; significant HDM-2 was found in the membranes of a variety of cancer cells but not several untransformed lines; PNC-27 colocalised with membrane-bound HDM-2; and transfecting membrane-targeted full-length HDM-2 into untransformed MCF-10-2A cells made them susceptible to PNC-27.
PNC-28, a p53-derived peptide that is cytotoxic to cancer cells, blocks pancreatic cancer cell growth in vivo Preclinical only
The related shorter analogue PNC-28 was cytotoxic to cancer cells and inhibited pancreatic tumour growth in a xenograft model.
The penetratin sequence in the anticancer PNC-28 peptide causes tumor cell necrosis rather than apoptosis of human pancreatic cancer cells Preclinical only
Established that the membrane-penetrating leader drives cell death by necrosis rather than apoptosis, consistent with a pore-formation mechanism.
The anti-cancer peptide, PNC-27, induces tumor cell necrosis of a poorly differentiated non-solid tissue human leukemia cell line that depends on expression of HDM-2 in the plasma membrane of these cells Preclinical only
K562 cells strongly expressed HDM-2 in their membranes and PNC-27 colocalised with it; PNC-27, but not the negative control peptide PNC-29, was selectively cytotoxic to K562 cells with nearly 100 percent killing and LDH release, while having no effect on the lymphocyte controls. Killing was p53-independent.
PNC-27, a Chimeric p53-Penetratin Peptide Binds to HDM-2 in a p53 Peptide-like Structure, Induces Selective Membrane-Pore Formation and Leads to Cancer Cell Lysis Preclinical only
Calculations suggest 1:1 PNC-27:HDM-2 complexes with the leader sequence pointing away; immuno-EM found 6 nm and 15 nm gold particles in roughly 1:1 ratios in layered ring-shaped structures in pores near the cell surface. No pores formed in PNC-27-treated untransformed fibroblasts.
Anti-Cancer Peptide PNC-27 Kills Cancer Cells by Unique Interactions with Plasma Membrane-Bound hdm-2 and with Mitochondrial Membranes Causing Mitochondrial Disruption Preclinical only
A monoclonal antibody against the p53 binding site of HDM-2 blocked PNC-27-induced necrosis while control immune serum did not; treated cells failed to retain mitotracker dye while retaining lysotracker dye; and gold-labelled anti-PNC-27 antibody localised to mitochondrial membranes.
Safety
There is no human safety data for PNC-27. None. No phase 1 trial has established a tolerated dose, no toxicity profile exists, and no adverse event reporting system covers it. Preclinical work suggests selectivity for transformed cells, but selectivity in cell culture routinely fails to predict organ toxicity in a whole animal, let alone a person, and a peptide whose mechanism is membrane pore formation carries obvious hazard if the selectivity assumption breaks down in vivo.
The documented harm is contamination. FDA laboratory testing of a PNC-27 inhalation solution sold through a commercial website identified the bacterium Variovorax paradoxus. FDA reporting on this matter has been updated since the original notice and further contamination findings have been described; because we could not re-verify the full current text of the FDA notice during this review, readers should consult the FDA warning directly rather than any secondary summary, including this one. What is not in doubt is the principle: cancer patients are frequently immunocompromised by their disease and its treatment, and non-sterile material sold for inhalation or injection into that population is a serious hazard. The 'for research use only' framing under which such material circulates is a legal device permitting the sale of unapproved compounds to consumers; it implies nothing about sterility, identity or purity, and here demonstrably did not deliver them.
Regulatory status
| Jurisdiction | Status |
|---|---|
| United Kingdom | No MHRA marketing authorisation. Supply for human use would fall under the Human Medicines Regulations 2012 as an unlicensed medicinal product, and promoting it as a cancer treatment would additionally breach the Cancer Act 1939, which prohibits advertising any offer to treat or cure cancer to the general public. |
| United States | Not FDA-approved for any indication. The FDA has warned consumers not to purchase or use PNC-27 products marketed as a treatment or cure for cancer, having identified bacterial contamination (Variovorax paradoxus) in a PNC-27 inhalation solution sample sold online. Marketing it as a cancer treatment constitutes distribution of an unapproved new drug with fraudulent health claims, and the agency has pursued enforcement against sellers of unapproved products claiming to treat cancer. Consult the current FDA notice directly for the full findings. |
| WADA (sport) | Prohibited under S0 (Non-Approved Substances), which covers at all times any pharmacological substance not addressed elsewhere on the List and holding no current approval by any governmental regulatory health authority for human therapeutic use. |
Questions
No. Every published study is in cell culture or animal xenografts. There has never been a human clinical trial of PNC-27: no phase 1, no registered study, no published human outcome data. The step from killing cancer cells in a dish to treating a person is where most oncology candidates fail, and PNC-27 has not taken it.
The FDA warned consumers not to purchase or use PNC-27 products sold online as a treatment or cure for cancer, and reported finding the bacterium Variovorax paradoxus in a PNC-27 inhalation solution sample. The population buying it, cancer patients, is disproportionately immunocompromised, so non-sterile inhaled or injected material is a serious hazard. Check the current FDA notice directly for the full findings.
The proposed basis is that many transformed cells display HDM-2 in the plasma membrane while normal cells do not. PNC-27's p53 fragment binds that membrane HDM-2, and the complexes assemble into pores that lyse the cell. Two controls support the model: the control peptide PNC-29, with the same leader and different cargo, does not kill cancer cells; and untransformed cells engineered to express membrane HDM-2 become susceptible. Those are well-designed in vitro observations, not demonstrated clinical selectivity.
Only loosely. It uses a fifteen-residue fragment of p53, but the proposed mechanism explicitly does not involve restoring p53 tumour-suppressor function inside the cell. It kills p53-null cells perfectly well. It is a membrane-lysis mechanism that happens to use a p53-derived sequence as a targeting address.